PEGylated rFVIII in Severe Haemophilia A Patients Undergoing Surgery

• Research type

  Research Study

• Full title

  A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures

• IRAS ID

  131147

• Contact name

  Andrew Will

• Contact email

  Andrew.Will@cmft.nhs.uk

• Sponsor organisation

  Baxter Innovations GmbH

• Eudract number

  2013-001359-11

• REC name

  East of Scotland Research Ethics Service REC 2

• REC reference

  13/ES/0103

• Date of REC Opinion

  17 Dec 2013

• REC opinion

  Further Information Favourable Opinion